CyLip-10
CyLip-10 is a microbial-derived cyclic-lipid antimicrobial peptide. CyLip-10 has broad-spectrum antimicrobial efficacy, low hemolytic activity, and excellent stability. CyLip-10 can disrupt membrane integrity, inhibit biofilm formation and induce membrane permeabilization and bacterial cell death. CyLip-10 reduces bacterial load, promotes wound healing, and alleviates inflammatory responses in a mouse Methicillin (HY-121544)-resistant Staphylococcus aureus skin wound infection model. CyLip-10 can be used for the bacterial infection.
For research use only. We do not sell to patients.
- Formula: C67H107N17O13
- Molecular Weight:1358.67
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
CyLip-10 (18-24 h) exhibits broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacterial strains (including S. aureus ATCC 25923, B. subtilis ATCC 23857, E. coli ATCC 25922, K. pneumoniae ATCC 700603, and P. aeruginosa ATCC 27853) with a GMall (the
geometric mean of the MICs) of 7.34 μM[1].
CyLip-10 (1 h) shows low hemolytic toxicity against mouse red blood cells with an HC10 value of >256 μM[1].
CyLip-10 (1 h) has low cytotoxicity against HK-2 cells with a CC50 value of 210 μM[1].
CyLip-10 exhibits good serum stability in mouse serum with a half-life exceeding 48 h[1].
CyLip-10 maintains complete antimicrobial activity against S. aureus and E. coli after 6 h incubation with 2000 μg/mL of trypsin or chymotrypsin[1].
CyLip-10 (8-32 μM; 2-24 h) rapidly kills S. aureus and E. coli and inhibits the formation of biofilms[1].
CyLip-10 has a low propensity to induce resistance in S. aureus and P. aeruginosa over 20 passages[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human kidney proximal tubular epithelial cells (HK-2)
-
Concentration:up to 128 μM
-
Incubation Time:1 h
-
Result:Maintained a cell survival rate exceeding 50% even at the highest concentration of 128 μM.
Achieved a CC50 value of 210 μM.
CyLip-10 (30-100 mg/kg; i.p.; single dose) has lower in vivo toxicity with an LD50 of 49.40 mg/kg in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/C (male, 6−8 weeks old, 20±2 g, MRSA-induced skin wound infection model)[1]
-
Dosage:2 mg/mL
-
Administration:Topical; six doses at 1-hour intervals
-
Result:Significantly reduced MRSA bacterial load in wounds compared to the model group.
Reduced serum TNF-α levels.
Produced wound areas smaller than the model group by day 4 and nearly healed by day 8.
Improved skin tissue structure with distinct epidermis and dermis layers, less inflammatory cell infiltration, and basically normal cell morphology.
Chemical Information
-
Molecular Weight 1358.67
-
Formula C67H107N17O13
-
Sequence
C8-{Dab}-{Dab}-{D-Tyr}-Lys-{Dab}-{Dab}-Trp-{D-Leu}-{D-Leu}-Glu (Lactam bridge: Lys4-Glu10)
-
Sequence Shortening
C8-{Dab}-{Dab}-{D-Tyr}-K-{Dab}-{Dab}-W-{D-Leu}-{D-Leu}-E (Lactam bridge: Lys4-Glu10)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)